Tricyclic-heteroaryl compounds useful as kinase inhibitors

Details Tricyclic-heteroaryl compounds useful as kinase inhibitors Tricyclic-heteroaryl compounds useful as kinase inhibitors

2007-08-07

2007-08-07

Balasubramanian, Venkataraman (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S184000

Reexamination Certificate

active

11170571

ABSTRACT:
The present invention relates to compounds having the formula,wherein, Q is optionally substituted aryl or heteroaryl, R1is hydrogen or C1-4alkyl, and R2, R3, R4and R5are hydrogen or optional substituents as defined in the specification.

REFERENCES:
patent: 4200750 (1980-04-01), Warner, Jr. et al.
patent: 5712279 (1998-01-01), Biller et al.
patent: 5739135 (1998-04-01), Biller et al.
patent: 5760246 (1998-06-01), Biller et al.
patent: 6184231 (2001-02-01), Hewawasam et al.
patent: 6548529 (2003-04-01), Robl et al.
patent: 6670357 (2003-12-01), Leftheris et al.
patent: 6706720 (2004-03-01), Atwal et al.
patent: 6867300 (2005-03-01), Godfrey, Jr. et al.
patent: 6869952 (2005-03-01), Bhide et al.
patent: 6906067 (2005-06-01), Moriarty et al.
patent: 6908916 (2005-06-01), Mastalerz et al.
patent: 6916813 (2005-07-01), Atwal et al.
patent: 6916815 (2005-07-01), Vite et al.
patent: 6933386 (2005-08-01), Bhide et al.
patent: 6951859 (2005-10-01), Bhide et al.
patent: 2002/0065270 (2002-05-01), Moriety et al.
patent: 2003/0139435 (2003-07-01), Ahmed et al.
patent: 2003/0186982 (2003-10-01), Godfrey, Jr.
patent: 2003/0232831 (2003-12-01), Dyckman et al.
patent: 2004/0023992 (2004-02-01), Das et al.
patent: 2004/0063707 (2004-04-01), Bhide et al.
patent: 2004/0082582 (2004-04-01), Dyckman et al.
patent: 2004/0157846 (2004-08-01), Chen et al.
patent: 2004/0229877 (2004-11-01), Leftheris et al.
patent: 2005/0043306 (2005-02-01), Leftheris et al.
patent: 2005/0143398 (2005-06-01), Das et al.
patent: 2005/0182058 (2005-08-01), Fink et al.
patent: 2005/0209454 (2005-09-01), Swaminathan et al.
patent: WO 02/062804 (2002-08-01), None
patent: WO 03/080047 (2003-10-01), None
patent: WO 03/090912 (2003-11-01), None
Wolft Manfred E. “Burger's Medicinal Chemistry, 5ed, Part 1”, John Wiley & Sons, 1995, pp. 975-977.
Banker, G.S. et al, “Modern Pharmaceutices, 3ed.”, Marcel Dekker, New York. 1996, pp. 451 and 596.
Nagarkatti et al. J. Mol. Cell Cardiol. 30(8): 1651-1664, 1998.
Brunet et al., Esaays Biochem. 32 : 1-16, 1997.
Herlaar et al. Mol. Med. Today 5(10) 439-447, 1999.
Graninger et al. Curr. Opin. Rheumatol. 13(3): 209-213.
U.S. Appl. No. 09/573,829, filed May 18, 2000.
U.S. Appl. No. 11/019,899, filed Dec. 22, 2004.
U.S. Appl. No. 11/111,144, filed Apr. 21, 2005.
U.S. Appl. No. 11/152,650, filed Jun. 14, 2005.
U.S. Appl. No. 11/157,460, filed Jun. 21, 2005.
U.S. Appl. No. 11/168,682, filed Jun. 28, 2005.
U.S. Appl. No. 11/199,746, filed Aug. 9, 2005.
U.S. Appl. No. 60/620,784, filed Oct. 21, 2004.
Ahn, H.-S. et al., “Potent Tetracyclic Guanine Inhibitors of PDE1 and PDE5 Cyclic Guanosine Monophosphate Phosphodiesterases with Oral Antihypertensive Activity”, J. Med. Chem., vol. 40, No. 14, pp. 2196-2210 (1997).
Bundgaard, H., Chapter 5: “Design and Application of Prodrugs”, A Textbook of Drug Design and Development, Harwood Academic Publishers, Publ., Krogsgaard-Larsen, P. et al., eds., pp. 113-191 (1991).
Bundgaard, H., ed., Design of Prodrugs, Elsevier Science Publishers B.V., publ. (1985) (table of contents).
Henry, J.R. et al., “p38 mitogen-activated protein kinase as a target for drug discovery”, Drugs of the Future, vol. 24, No. 12, pp. 1345-1354 (1999).
Jaffari, G.A. et al., “Some Oxidation Reactions of Monochloramine”, J. Chem. Soc. (C), pp. 823-826 (1971).
Kakeya, N. et al., “Studies on Prodrugs of Cephalosporins. I. Synthesis and Biological Properties of Glycyloxybenzoyloxmethyl and Glycylaminobenzoyloxymethyl Esters of 7β-[2-(2-Aminothiazol-4-yl)-(Z)-2-methoxyiminoacetamido]-3-methyl-3-cephem-4-carboxylic Acid”, Chem. Pharm Bull., vol. 32, No. 2, pp. 692-698 (1984).
Manning, G. et al., “The Protein Kinase Complement of the Human Genome”, Science, vol. 298, pp. 1912-1916, 1933-1934 (2002).
Moreland, L.W. et al., “Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial”, Ann. Intern. Med., vol. 130, No. 6, pp. 478-486 (1999).
Nielsen, N.M. et al., “Glycolamide Esters as Biolabile Prodrugs of Carboxylic Acid Agents: Synthesis, Stabilty, Bioconversion, and Physicochemical Properties”, Journal of Pharmaceutical Sciences, vol. 77, No. 4, pp. 285-298 (1988).
Raingeaud, J. et al., “MKK3- and MKK6-Regulated Gene Expression Is Mediated by the p38 Mitogen-Activated Protein Kinase Signal Transduction Pathway”, Molecular and Cellular Biology, vol. 16, No. 3, pp. 1247-1255 (1996).
Rankin, E.C.C. et al., “The Therapeutic Effects of an Engineered Human Anti-Tumour Necrosis Factor Alpha Antibody (CDP571) in Rheumatoid Arthritis”, British Journal of Rheumatology, vol. 34, No. 4, pp. 334-342 (1995).
Salituro, F.G. et al., “Inhibitors of p38 MAP Kinase: Therapeutic Intervention in Cytokine-Mediated Diseases”, Current Medicinal Chemistry, vol. 6, No. 9, pp. 807-823 (1999).
Seli{hacek over (c)} , L. et al., “Transformations of Alkyl 2-(2,2-Disubstituted-ethenyl)amino-3-dimethylaminoprop-2-enoates: Synthesis of Alkyl 3,4-Disubstituted- and Alkyl 1-Acyl-3,4-disubstituted Pyrrole-2-carboxylates”, Synthesis, No. 3, pp. 479-482 (1999).
Svete, J. et al., “2-Benzoyl-2-ethoxycarbonylvinyl-1 and 2-Benzoylamino-2-methoxycarbonylvinyl-1 asN-Protecting Groups in Peptide Synthesis. Their Application in the Synthesis of Dehydropeptide Derivatives ContainingN-Terminal 3-Heteroarylamino-2,3-dehydroalanine”, J. Heterocyclic Chem., vol. 34, pp. 177-193 (1997).
Toplak, R. et al., “Ethyl 2-(2-acetyl-2-ethoxycarbonyl-1-ethenyl)amino-3-dimethylaminopropenoate in the Synthesis of Heterocyclic Systems. The Synthesis of Substituted 3-Aminoazolo- and -Azinopyrimidinones, Pyridopyridinones and Pyranones”, Heterocycles, vol. 50, No. 2, pp. 853-866 (1999).
Widder, K.J. et al., eds., Section III: “Prodrugs”, Methods in Enzymology, vol. 112, Academic Press, Inc., publ., pp. 309-396 (1985).
Yet, L., “Peptide Coupling Reagents: Names, Acronyms and References”, Technical Reports, Albany Molecular Research, Inc., vol. 4, No. 1, pp. 1-7 (1999).
Branger, J., et al., “Anti-Inflammatory Effects of a p38 Mitogen-Activated Protein Kinase Inhibitor During Human Endotoxemia” The Journal of Immunology, vol. 168, pp. 4070-4077, (2002).
Davis, J. C., Jr., “Understanding the Role of Tumor Necrosis Factor Inhibition in Ankylosing Spondylitis”, Seminars in Arthritis and Rheumatism, vol. 34, pp. 668-677, (2004).
Gottlieb, A. B., et al., TNF Inhibition Rapidly Down-Regulates Multiple Proinflammatory Pathways in Psoriasis Plaques1, The Journal of Immunology, vol. 175, pp. 2721-2729, (2005).
Hideshima, T. et al, “Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu”, Blood, vol. 101(2), pp. 703-706, (2003).
Johansen, C., et al., “Protein Expression of TNF-α in Psoriatic Skin Is Regulated at a Posttranscriptional Level by MAPK-Activated Protein Kinase 21”, The Journal of Immunology, vol. 176, pp. 1431-1438, (2006).
Johansen, C., et al., “The mitogen-activated protein kinases p38 and KRK1/2 are increased in lesional psoriatic skin”, British Journal of Dermatology, vol. 152, pp. 37-42, (2005).
Kumar, S., et al., “P38 MAP Kinases: Key Signalling Molecules as Therapeutic Targets for Inflammatory Diseases”, vol. 2, pp. 717-726, (2003).
Mease, P. J., et al., “Psoriatic arthritis treatment: biological response modifiers”, Ann. Rheum. Dis., vol. 64 (Suppl. II), pp. ii78-ii82, (2005).
Navas, TA, et al., Inhibition of p38α MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-XL, MCI-1 and p53 levels in vitro and inhibits tumor growth in vivo, Leukemia, 1-11 (2006).
Papp. K. A., “The long-term efficacy and safety of new biological therapies for psoriasis”, Arch. Dermatol. Res. vol. 298, pp. 7-16, (2006).
Saklatvala, J., “The p38 MAP Kinase pathway as a therapeutic target in inflammatory disea

Affiliated with

Also associated with

Rating

Tricyclic-heteroaryl compounds useful as kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tricyclic-heteroaryl compounds useful as kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tricyclic-heteroaryl compounds useful as kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3865136